The zoonotic malaria parasite Plasmodium knowlesi has recently been established in continuous in vitro culture. Here, the Plasmodium falciparum [ 3 H]hypoxanthine uptake assay was adapted for P. knowlesi and used to determine the sensitivity of this parasite to chloroquine, cycloguanil, and clindamycin. The data demonstrate that P. knowlesi is sensitive to all drugs, with 50% inhibitory concentrations (IC 50 s) consistent with those obtained with P. falciparum. This assay provides a platform to use P. knowlesi in vitro for drug discovery.
I
n 2015, there were an estimated 214 million clinical cases of malaria which resulted in ϳ438,000 deaths (1). Substantial funds have been invested in producing a malaria vaccine; however, the efficacy of experimental vaccines has been poor (2, 3) , and as a result, vector control and drugs remain the mainstays for the prevention and treatment of malaria. While there has been a significant reduction in malaria-associated mortality and morbidity in recent years (1), there is concern that lack of sustained funding, together with insecticide and antimalarial drug resistance, will affect this progress (4) . To prevent backward momentum in disease control and push toward the endgame strategy of malaria elimination, new chemotherapeutics with novel modes of action and activity against multiple species and life cycle stages are needed (5) .
The ability to easily and rapidly assess the activity of new lead compounds against multiple Plasmodium species has been limited to date, as only Plasmodium falciparum has been amenable to routine, long-term, continuous in vitro culture (6) . While there have been some recent improvements to in vitro culture techniques for Plasmodium vivax, the culture of this parasite is still limited by the requirement of reticulocytes, and the parasite density over longterm culture is low (7) . However, the recent adaptation of the zoonotic malaria species Plasmodium knowlesi (8) to continuous in vitro culture in human erythrocytes (9) (10) (11) has changed this position. Although a routine drug sensitivity assay for P. knowlesi has not yet been established, the ability to culture this parasite species in vitro provides researchers with an unprecedented opportunity to rapidly test new drug leads against two human-infecting Plasmodium species.
In vitro assays for assessing malaria parasite growth inhibition are indispensable tools for the screening and evaluation of potential new drug leads and, also, for the surveillance of parasite drug resistance. A "gold standard" approach for assessing P. falciparum growth inhibition is the incorporation of [ 3 H]hypoxanthine into parasite nucleic acids (12) . As Plasmodium parasites are unable to synthesize purines de novo, they must scavenge these metabolic precursors for growth. Thus, supplementation of parasite cultures with [ 3 H]hypoxanthine results in the incorporation of this radiolabeled purine into nucleic acids, permitting growth to be quantitated using a scintillation counter. While there are a number of other methods available to assess in vitro proliferation and growth inhibition of Plasmodium parasites (e.g., enzymatic assays, such as the parasite lactate dehydrogenase assay [13] , and dye-based fluorescence assays, such as those that use SYBR green I or 4=,6-diamidino-2-phenylindole [DAPI] [14] ), the [ 3 H]hypoxanthine incorporation assay remains a gold standard approach and is used as a reference for other approaches. In this study, the [ 3 H]hypoxanthine incorporation assay was assessed for use with P. knowlesi strain A1H.1 in vitro-adapted parasites (11) .
The effect of starting parasitemia at two different hematocrits (1% versus 2%) was assessed by seeding P. knowlesi A1H.1 parasites into 96-well tissue culture plates, followed by the addition of [ 3 H]hypoxanthine (0.5 Ci/well). Cultures were then maintained under standard culture conditions (11) (15) .
No significant difference in [ 3 H]hypoxanthine incorporation was observed for cultures seeded at 1% (Fig. 1A) versus 2% (Fig. 1B) hematocrit over 24 h (P Ͼ 0.45), 48 h (P Ͼ 0.06), or 72 h (P Ͼ 0.09). As would be expected, the 24-h assays yielded comparatively low levels of [ 3 H]hypoxanthine incorporation compared to the levels obtained in the 48-h and 72-h assays (Fig. 1A and B), with a starting parasitemia of below 0.0625% resulting in Z-factors of Ͻ0.5 (marginal assay conditions). For the 48-h and 72-h assays, Z-factors of 0.5 to 1.0 were obtained for all starting parasitemias, indicating excellent assays (15) . However, when assessed for 48 h or 72 h, the levels of [
3 H]hypoxanthine incorporation of cultures with a starting parasitemia of Ն0.5% were seen to plateau and decline in some instances, suggesting overgrowth and/or parasite death. For this reason, assays to assess drug activity were performed using a 0.25% starting parasitemia and 2% hematocrit (Z-factor of 0.87 Ϯ 0.07 [mean Ϯ standard deviation]).
The [ 3 H]hypoxanthine incorporation assay described above was used to assess the activities of chloroquine, cycloguanil, and clindamycin against P. knowlesi A1H.1. Chloroquine and cycloguanil are fast-acting drugs which act in the first P. falciparum asexual intraerythrocytic developmental cycle (16, 17) , while clindamycin is a slow-acting drug with a "delayed-death" phenotype that is not observable until after two asexual intraerythrocytic developmental cycles (16) . The activity of all three drugs was assessed against P. knowlesi A1H.1 using asynchronous parasites (0.25% parasitemia and 2% hematocrit) over 24 h, 48 h, or 72 h. Three independent assays (in triplicate wells) were carried out, and the resulting 50% inhibitory concentrations (IC 50 s) determined by log-linear interpolation (18) (20) . While there were significant differences in the IC 50 s for cycloguanil at 24 h versus 48 h and 72 h (Table 1) (P Ͻ 0.05), there was no significant difference between the 48-h and 72-h IC 50 s (Table 1 ) (P ϭ 0.540). In contrast to the P. knowlesi A1H.1 chloroquine and cycloguanil data, clindamycin had 24-h and 48-h IC 50 s of Ͼ10 M, compared to an IC 50 of 0.0030 Ϯ 0.001 M in the 72-h assay, consistent with the delayed-death phenotype reported for P. falciparum with this drug (21, 22) . This translates to a Ͼ670-fold-lower IC 50 at 72 h than at 24 h or 48 h, more than 2 orders of magnitude higher than the difference at 72 h versus 24 h or 48 h for the fast-action compounds chloroquine and cycloguanil.
To our knowledge, this is the first study to use [ 3 H] hypoxanthine uptake as a method to assess drug activity against in vitro culture-adapted P. knowlesi grown in human erythrocytes and the first to report on the in vitro sensitivity of clinically used antimalarial drugs against this culture-adapted Plasmodium species. This work paves the way for additional studies with culture-adapted P. knowlesi as an in vitro model for drug discovery, until now limited to the use of P. falciparum due to the inability to easily and routinely culture sufficient quantities of other Plasmodium species in vitro. Such studies include those designed to better understand growth dynamics and drug action, including in vitro drug combination studies (isobolograms) and adaptation of assays such as the P. falciparum parasite reduction ratio (PRR) assay (23) to assess the speed of drug action on the parasite.
